Strategies to Improve Long-Term Outcome in Stage IIIB Inflammatory Breast Cancer: Multimodality Treatment Including Dose-Intensive Induction and High-Dose Chemotherapy

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 8, 2009, Pages 963-970

  Sportès, Claude ^a   Steinberg, Seth M ^a   Liewehr, David J ^a   Gea Banacloche, Juan ^a   Danforth, David N ^a   Avila, Daniele N ^a   Bryant, Kelly E ^a   Krumlauf, Michael C ^a   Fowler, Daniel H ^a   Pavletic, Steven ^a   Hardy, Nancy M ^a   Bishop, Michael R ^a   Gress, Ronald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autologous transplantation; High dose chemotherapy; Inflammatory breast cancer; Multimodality therapy

Indexed keywords

ACICLOVIR; ANASTROZOLE; ANTHRACYCLINE; ANTIEMETIC AGENT; CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MESNA; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HERPES SIMPLEX; HUMAN; INFLAMMATORY BREAST CANCER; LONG TERM CARE; MASTECTOMY; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATION; MELPHALAN; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67649619558     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.04.018     Document Type: Article

References (41)

1. Ellis D.L., and Teitelbaum S.L. Inflammatory carcinoma of the breast. A pathologic definition. Cancer 33 (1974) 1045-1047
2. Fleming R.Y., Asmar L., Buzdar A.U., et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 4 (1997) 452-461
3. Gurney H., Harnett P., Kefford R., et al. Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. Aust N Z J Med 28 (1998) 400-402
4. Ueno N.T., Buzdar A.U., Singletary S.E., et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 40 (1997) 321-329
5. Low J.A., Berman A.W., Steinberg S.M., et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 22 (2004) 4067-4074
6. Hance K.W., Anderson W.F., Devesa S.S., et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97 (2005) 966-975
7. De Boer R.H., Allum W.H., Ebbs S.R., et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery?. Ann Oncol 11 (2000) 1147-1153
8. Brooks H.L., Mandava N., Pizzi W.F., et al. Inflammatory breast carcinoma: a community hospital experience. J Am Coll Surg 186 (1998) 622-629
9. Tokuda Y., Tajima T., Narabayashi M., et al. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci 99 (2008) 145-151
10. Nitz U.A., Mohrmann S., Fischer J., et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366 (2005) 1935-1944
11. Roche H., Viens P., Biron P., et al. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10 (2003) 42-47
12. Rodenhuis S., Bontenbal M., Beex L.V., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349 (2003) 7-16
13. Tallman M.S., Gray R., Robert N.J., et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349 (2003) 17-26
14. Moore H.C., Green S.J., Gralow J.R., et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol 25 (2007) 1677-1682
15. Hortobagyi G.N., Buzdar A.U., Theriault R.L., et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92 (2000) 225-233
16. Hanrahan E.O., Broglio K., Frye D., et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106 (2006) 2327-2336
17. Peters W.P., Rosner G.L., Vredenburgh J.J., et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23 (2005) 2191-2200
18. Coombes R.C., Howell A., Emson M., et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with 4 or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol 16 (2005) 726-734
19. Leonard R.C., Lind M., Twelves C., et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 96 (2004) 1076-1083
20. Zander A.R., Kroger N., Schmoor C., et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 22 (2004) 2273-2283
21. Bergh J., Wiklund T., Erikstein B., et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356 (2000) 1384-1391
22. Gianni A.M., Bonadonna G., Michelangelo G., et al. Updated 12-year results of a randomized clinical trial comparing standard-dose to high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than 3 positive nodes (LN+). ASCO Meet Abstr 25 (2007) 549
23. Basser R., O'Neill G., Martinelli G., et al. Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): first results from the IBCSG Trial 15-95. Proc Am Soc Clin Oncol 22 (2003) 6
24. Farquhar C.M., Marjoribanks J., Lethaby A., et al. High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 33 (2007) 325-337
25. Ueno N.T., Berry D.A., Johnson M.M., et al. High-dose chemotherapy with a stem cell support-versus-standard dose chemotherapy: meta-analysis of individual patient data from 15 randomised breast cancer trial. Biol Blood Marrow Tranplant 14 (2008) 91
26. Rosti G., Ferrante P., Ledermann J., et al. High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol/Hematol 41 (2002) 129-140
27. Sportes C., McCarthy N.J., Hakim F., et al. Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients. Biol Blood Marrow Transplant 11 (2005) 472-483
28. Cristofanilli M., Buzdar A.U., Sneige N., et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92 (2001) 1775-1782
29. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
30. Viens P., Penault-Llorca F., Jacquemier J., et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 21 (1998) 249-254
31. Adkins D., Brown R., Trinkaus K., et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol 17 (1999) 2006-2014
32. Arun B., Slack R., Gehan E., et al. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer 85 (1999) 93-99
33. Schwartzberg L., Weaver C., Lewkow L., et al. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant 24 (1999) 981-987
34. Viens P., Palangie T., Janvier M., et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 81 (1999) 449-456
35. Macquart-Moulin G., Viens P., Palangie T., et al. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?. [In Process Citation]. J Clin Oncol 18 (2000) 754
36. Viens P., and Maraninchi D. High-dose chemotherapy in advanced breast cancer. Crit Rev Oncol Hematol 41 (2002) 141-149
37. Cagnoni P.J., Nieto Y., Shpall E.J., et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 16 (1998) 1661-1668
38. Nieto Y., Nawaz S., Shpall E.J., et al. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res 10 (2004) 2609-2617
39. Ayash L.J., Elias A., Ibrahim J., et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 16 (1998) 1000-1007
40. Dazzi C., Cariello A., Rosti G., et al. Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study. Haematologica 86 (2001) 523-529
41. Tolcher A.W., Cowan K.H., Noone M.H., et al. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14 (1996) 95-102